National Chronicle
National National Chronicle Special

Natural phytochemicals in ashwagandha, giloy, tulsi can fight Covid: Patanjali (Special)

Patanjali Research Institute

New Delhi: Ramdevs Patanjali Research Institute (PRI), which has developed Coronil that has been claimed as a cure for Covid-19, has discovered that natural phytochemicals in ashwagandha, giloy and tulsi have the potential to combat Covid-19 and its pathogenicity.

The prescribed intervention includes ashwagandha, giloy, tulsi, anu taila and swasari ras. The research and trials were conducted at the NIMS University in Jaipur.

The Covid-19 infection is known to affect individuals with weak immunity more severely. “Therefore, enhancing immunity is definitely one of the ways the doctors across the globe have been using for treating Covid 19 cases,” according to a Patanjali report.

According to the report, to combat Covid-19 with Ayurveda, “we have screened close to 1,000 phytochemicals from more than 100 medicinal plants. We looked for their binding affinities to Covid-19 essential proteins and host protein interactions.”

“We have discovered that natural phytochemcials in ashwagandha, giloy and tulsi have the potential to combat Covid-19 and its pathogenicity,” Patanjali said.

In reply to a questionnaire from the Ministry of Ayush, the Patanjali Research Institute, Haridwar, pointed out that the clinical trials for the Ayurvedic medicines were conducted and registered with the Clinical Trial Registry of India (CTRI) as per the guidelines of the Clinical Evaluation of Ayurvedic Interventions by the Central Council for Research in Ayurvedic Sciences, Ministry of Ayush.

The Patanjali reply signed by Acharya Balkrishna said the clinical trials were also communicated to the Director General of the Council in an email by the Principal Investigator, Ganpat Devpura.

Related posts

Tech firm deploys data analysis tools to help check COVID-19

IANS

US calls China ‘rogue actor’, blames it for face-off with India

IANS

Delhi Metro to remain shut ‘until further notice’

IANS

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More